GlassScriptPhysician profile
Richard S Rhee
NPI 1659346112
$13,474.17
in general payments reported to CMS, 2019-2025
76 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,168 · 2020: $2,380 · 2021: $3,162 · 2022: $2,712 · 2023: $1,675 · 2024: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,052.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,390.63 | 2019-2023 | Briviact, Nayzilam |
| Novartis Pharmaceuticals Corporation | $1,238.81 | 2019-2023 | |
| Biogen, INC. | $1,234.78 | 2019-2023 | Vumerity, Spinraza |
| Teva Pharmaceuticals USA, INC. | $694.62 | 2019-2024 | Austedo Xr, Ajovy, Austedo |
| Sunovion Pharmaceuticals INC. | $687.53 | 2019-2022 | |
| Emd Serono, INC. | $661.67 | 2019-2024 | Mavenclad |
| Amgen INC. | $603.53 | 2019-2022 | |
| Abbvie INC. | $598.08 | 2021-2024 | |
| Celgene Corporation | $346.30 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $317.14 | 2019-2024 | Reyvow, Emgality, Amyvid |
| Neurelis, INC. | $296.02 | 2020-2023 | Valtoco |
| Sk Life Science, INC. | $266.07 | 2020-2024 | |
| Genzyme Corporation | $251.85 | 2019-2021 | |
| Csl Behring | $247.01 | 2019-2022 | |
| Genentech USA, INC. | $229.32 | 2019-2023 | Ocrevus |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Rhee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.